gp0531

The revenue problem telehealth providers are actually solving

Most telehealth companies do not have a demand problem. They have a *margin* problem disguised as a demand problem, and the difference determines whether the go-to-market motion you build in 2027 compounds or quietly bleeds cash for three years.

Here is the mechanic. A direct-to-consumer virtual visit is a low-ticket, low-frequency transaction. A single urgent-care-style video consult produces a modest one-time payment, and the patient often has no structural reason to come back — they had a rash, they got a prescription, they left. If you acquire that patient through paid search or paid social, you are paying a customer-acquisition cost that is frequently a multiple of the gross margin on the visit. The business only works if that patient returns several times, or if their episode leads to a longer relationship. In practice most one-off acute-care patients do not return within the year. So the unit economics require either a very cheap acquisition channel or a much longer revenue tail — and by 2027, cheap acquisition channels in healthcare have largely stopped existing. Health-related paid search is among the most expensive keyword inventory anywhere because you are bidding against health systems with brand budgets, retail entrants with balance sheets, pharma, insurers, and every other digital health company running the identical play.

The second half of the problem is that the thing you used to sell — access — got commoditized. In 2020 through roughly 2023, "you can see a doctor from your couch" was a genuine differentiator worth paying for. It is now an expected feature of virtually every payer, every large employer benefit stack, most health systems, and several national retail and pharmacy players. When a capability becomes ubiquitous, its price collapses toward the cost of delivery. That is exactly what happened to general virtual primary care and general urgent care: they are now something a health plan bundles rather than something a patient chooses and pays a premium for.

So the revenue problem being solved by the 2027 playbook is this: *how do you sell virtual care as an outcome rather than as an appointment?* The answer restructures everything downstream. If you sell appointments, your buyer is a patient, your channel is advertising, your price is a copay, and your growth curve is a treadmill. If you sell outcomes — fewer avoidable emergency department visits, better medication adherence in a diabetic population, faster behavioral health access that keeps an employee at work, shorter time-to-specialist that prevents an escalation — your buyer is a self-insured employer, a health plan, or a health system taking risk. Your channel becomes partnerships and enterprise sales. Your price becomes a per-member-per-month fee or a shared-savings arrangement. And your revenue becomes contracted, renewable, and forecastable instead of transactional.

That reframe has a hard consequence many teams resist: you must narrow. A provider that treats "everyone with a health need" as the market cannot produce a defensible outcomes claim for anyone, because outcome claims are cohort-specific. You cannot say "we reduce total cost of care" in the abstract. You can say "in an attributed population of employees with poorly controlled type 2 diabetes, our program improved medication adherence and reduced avoidable acute utilization over twelve months." The second sentence is sellable to a benefits leader. The first is noise. Narrowing is not a marketing choice in this playbook — it is a prerequisite for having anything to sell at all.

There is an adjacent lesson from vertical SaaS worth stealing here. Horizontal software companies that tried to serve every industry consistently lost enterprise deals to vertical specialists who spoke the buyer's operational language and shipped workflows that matched how that industry actually runs. Telehealth is following the same curve roughly a decade later. The generalist virtual-care platform is the horizontal tool; the condition-specific, population-specific program is the vertical product. In both cases the vertical player wins on shorter sales cycles, higher contract values, lower churn, and dramatically better proof.

Root-cause map: why generic telehealth GTM stalls

Before you rebuild the motion, it helps to trace the failure back through its actual causal chain rather than treating each symptom as its own project. Teams routinely try to fix high acquisition cost with better ad creative, or fix churn with a loyalty program, when both symptoms share a single upstream cause: an undifferentiated offer sold to an unaccountable buyer.

Read the map from the top. The root node is the undifferentiated offer. Everything below it is a consequence, which is why point fixes fail. Better creative lowers cost per click but does not change the fact that you are buying attention for a commodity. A loyalty program cannot manufacture clinical reasons to return that the offer never created. Discounting the visit fee accelerates the margin problem rather than solving it.

The two intervention nodes at the bottom are where the leverage sits. Narrowing to clinical niches creates the raw material for an outcome claim, which unlocks the enterprise buyer, which unlocks partner distribution, which collapses acquisition cost because someone else's trusted relationship does the introducing. That is the whole thesis of the 2027 playbook compressed into one causal chain.

One diagnostic worth running against your own business: for each dollar of new revenue last quarter, trace which node produced it. If most of it traces through the paid-consumer branch, you are running the pre-2024 playbook regardless of what your strategy deck says. If it traces through employer contracts, health-system referral flows, or plan-sponsored benefit inclusion, you are already on the durable side of the map and the work is deepening it rather than rebuilding it.

Note also what the map implies about sequencing. Teams often try to sign partners *before* they have an outcome claim, reasoning that distribution will buy them time to develop proof. This inverts the dependency. A broker or a health-system partner will take the meeting, may even sign a paper agreement, and then route no patients — because their own stakeholders ask "why should we send members here rather than to the plan's existing virtual benefit?" and the partner has no answer. Signed-but-dormant partnerships are the single most common failure mode in this category, and they are worse than no partnership at all: they consume integration engineering, legal review, and account management while returning nothing. The proof has to exist first, even in preliminary form, or the flywheel never turns.

Benchmarks, ranges, and the numbers that actually govern the model

Published industry benchmarks in digital health are unreliable enough that building a plan on borrowed numbers is a real risk — definitions of "utilization," "engagement," and "member" vary so widely between vendors that two companies can report the same metric with a threefold difference in meaning. The practical answer is to instrument your own baseline in the first two quarters and manage against internal targets, while using external figures only for directional context. That said, there are structural ranges and relationships that hold across the category and should shape your model.

Acquisition cost versus visit margin. The governing ratio is fully loaded acquisition cost divided by contribution margin per patient relationship, not per visit. If a patient produces one visit, the visit must carry the entire acquisition cost plus clinician cost plus platform cost. In practice this almost never works in paid consumer channels for acute care. Model it explicitly: take your all-in paid acquisition cost per activated patient, divide by contribution margin per visit, and the result is the number of visits that patient must generate before you break even. If that number exceeds your observed twelve-month return rate, the channel is structurally unprofitable and no optimization fixes it.

Payback period. Enterprise telehealth contracts should be modeled on a payback horizon measured in quarters, not months, because the sales cycle itself consumes real cost. A mid-market self-insured employer deal typically runs several months from first broker conversation to signed agreement, with a pilot period on top. Budget for a sales cycle in the range of two to four quarters for employer and payer deals, and longer for health-system co-management arrangements that require clinical governance review, credentialing, and often an EHR integration. Companies that model these deals on SaaS-like three-month cycles run out of runway.

Utilization is the metric that kills contracts. Employers buy telehealth benefits and then renew or cancel almost entirely on utilization. A benefit nobody uses is a line item a CFO removes at renewal, regardless of how good the clinical outcomes were for the handful who engaged. This is why activation, not enrollment, is the number to manage. Enrollment counts eligible lives; activation counts humans who completed a first meaningful interaction. The gap between them is where most programs die. Build your onboarding, communications, and incentive design around closing that gap, and report activation to the client monthly so nobody is surprised at renewal.

Contract value scales with population and scope, not with feature count. Per-member-per-month pricing against an eligible population produces predictable revenue but low absolute dollars if the population is small. Per-episode or per-engaged-member pricing produces higher realized revenue per active user but unpredictable totals. Shared-savings arrangements produce the highest ceiling and the highest risk, and they require an actuarial capability most early-stage providers do not have. A practical progression: start with PMPM for predictability, layer per-episode fees for high-acuity service lines, and only move to shared savings once you have twelve to twenty-four months of your own outcome data and someone on staff who can defend the attribution methodology under scrutiny.

Clinician capacity is the hidden constraint on growth. Unlike software, your delivery capacity is licensed humans. Every state you sell into requires appropriate licensure, and while interstate licensure compacts have materially reduced the friction, they have not eliminated it — compact participation varies by state and by profession, and behavioral health, nursing, and physician pathways each have their own rules. Model clinician recruitment lead time as a gating input to your sales plan. Selling a national employer with employees in forty states when your panel is licensed in twelve is how you win a contract and then fail the implementation, which is far more damaging than losing the deal.

Churn behaves differently by buyer. Consumer churn in acute virtual care is severe and largely structural. Employer-contract churn is annual and tied to the benefits renewal calendar, which means you have a predictable defense window but a single point of failure each year. Health-system partnership churn is slow but catastrophic when it happens, because those flows are integrated and hard to replace. Segment your retention work accordingly: consumer retention is a product problem, employer retention is a reporting and utilization problem, health-system retention is a relationship and clinical-integration problem.

A note on ROI models you hand to buyers. Build a calculator the buyer populates with *their own* claims data, headcount, and cost assumptions rather than one preloaded with your favorable figures. Sophisticated benefits consultants discount vendor-supplied savings numbers heavily, and rightly so. A model that takes their inputs and shows a conservative, clearly-labeled range is far more persuasive than a confident single number they have no reason to trust. State your assumptions on the slide. Show the downside case. Buyers who have been burned by digital health vendors — which by 2027 is most of them — respond to visible conservatism.

Trade-offs: the four channel choices and what each actually costs

There is no single correct distribution strategy, but there are four viable ones and they trade off against each other in ways worth being explicit about before you commit headcount.

Direct-to-employer through brokers and benefits consultants. This is the highest-leverage channel for most providers and the one the 2027 playbook leans on hardest. Brokers and consultants already hold trusted relationships with HR and benefits leaders, already run the annual renewal process, and already field the question "what should we add this year?" Getting into that consideration set is worth more than any amount of direct outbound. The cost: brokers are gatekeepers with their own economics, they will not push a product that creates support burden or that they cannot explain in one slide, and building broker relationships takes quarters of sustained effort with no revenue. You also inherit their calendar — most employer decisions cluster around the benefits planning cycle, which means you have a concentrated selling season and long dead stretches. The trade-off is high contract value and low churn in exchange for slow, seasonal, relationship-dependent growth.

Health system partnership and white-label. Community hospitals, FQHCs, and regional systems frequently lack the capital or engineering capacity to build competitive virtual infrastructure, and they hold something you cannot buy: existing patient relationships and referral pathways. A revenue-share or white-label arrangement lets them offer virtual specialty access under their own brand while you supply the clinical network and platform. The cost is real: these deals require clinical governance approval, credentialing, sometimes EHR integration work that runs months, and you give up brand equity because the patient experiences the hospital's name, not yours. You also become substitutable — if they build the capability internally later, you lose the flow. The trade-off is durable, high-volume, low-acquisition-cost patient flow in exchange for brand invisibility, integration cost, and strategic dependency.

Health plan and Medicare Advantage channels. Plans, and MA plans in particular, have been expanding supplemental virtual benefits and are structurally motivated to reduce avoidable utilization among members they hold risk on. This is the channel with the largest ceiling and the longest, most bureaucratic path. Procurement is formal, clinical review is rigorous, and the plan will want quality metrics that map to their own reporting obligations. The cost is time, compliance overhead, and the need for genuine actuarial credibility. The upside is that a single plan contract can deliver more attributed lives than a hundred employer deals.

Direct-to-consumer. Still viable in narrow circumstances: cash-pay services where the patient is motivated and the price point is high enough to absorb acquisition cost, categories with a strong organic search surface, and situations where a consumer brand creates pull that pressures employers and plans to add you. The cost is that you are competing for the most expensive advertising inventory in the economy against companies with deeper pockets. Treat DTC as a demand-generation and brand layer that supports enterprise selling rather than as a standalone revenue engine.

What about organic and content? Long-tail organic search remains genuinely underpriced relative to paid, and condition-plus-geography queries — the kind a patient types when they have a specific problem and a specific insurance card — convert far better than broad category terms. The trade-off is time: organic authority in health topics compounds slowly and is subject to search-quality standards that reward genuine clinical expertise and penalize thin content. Budget a year before it contributes meaningfully, and staff it with people who can produce medically reviewed material, not a general content agency.

The practical recommendation for most providers: pick one primary channel and one secondary, fund the primary at roughly seventy percent of GTM resources, and explicitly starve the rest for the first eighteen months. The most common resourcing error in this category is running four channels at thirty percent effectiveness each, which produces four sets of half-built enablement and no channel that works.

The proof engine: turning clinical activity into commercial evidence

Everything above depends on one capability most telehealth teams underbuild — the ability to convert what happens clinically into language a financial buyer accepts. Call it the proof engine, and treat it as a product surface with an owner, a roadmap, and a release cadence, not as a marketing deliverable produced once a year.

Start with instrumentation. Every encounter needs to be tagged at capture time with the attributes you will later need to build cohorts: condition, acuity, referral source, employer or plan attribution, prior utilization where you have visibility, and the clinical measures relevant to that program. Retrofitting this is painful and often impossible, which is why it belongs in the first engineering sprint of any new service line rather than the tenth. If you cannot construct a cohort, you cannot make a claim.

Then build the translation layer. A benefits leader does not think in clinical measures; they think in claims trend, absenteeism, disability days, and the specific line items their CFO questions. A payer medical director thinks in risk-adjusted quality measures, network adequacy, and total cost of care for an attributed population. A health-system partner thinks in referral leakage, capacity, and downstream procedure volume. The same clinical result must be expressible in all three vocabularies, and your sales team should never be improvising that translation in the room.

The highest-conversion move in this whole playbook is showing a prospect a live preview of the reporting they will receive, during the sales cycle, before they sign anything. Most digital health vendors promise data "once you're live." Showing the actual dashboard — with anonymized or sample data if necessary — with the exact metrics, the exact cadence, and the exact caveats you will report converts skepticism into trust faster than any case study, because it makes an implicit commitment explicit and verifiable. It also disciplines your own team: you cannot show a dashboard you have not built.

Be rigorous about attribution and honest about its limits. Selection effects are real in virtual care — patients who opt into a program are systematically different from those who do not, usually more engaged and often healthier. Any savings claim that ignores this will be dismantled by a competent consultant. Address it before they raise it: describe your comparison approach, name its limitations, and present ranges rather than points. Sophisticated buyers trust a vendor who volunteers the weakness in their own analysis far more than one who presents a clean number and gets caught.

Finally, publish the negative findings internally. Service lines that do not produce a defensible outcome should be identified quickly and either redesigned or shut down. The proof engine's most valuable output is not the case study; it is the early signal that a program is not working, delivered while you can still fix it rather than at renewal when the client tells you.

Rollout plan: sequencing the first four quarters

The sequencing matters as much as the strategy, because several of these workstreams are dependencies for others and running them in the wrong order wastes a year. The flow below assumes a provider with an existing clinical capability that is repositioning from a generalist or consumer motion toward the partner-led, outcomes-priced model.

A few notes on the sequence. Quarter one is deliberately unglamorous — narrowing the offer and instrumenting encounters produces no revenue and looks like internal work, which is why teams under pressure skip it and then spend quarter three unable to answer a buyer's first question. Protect it.

Quarter two builds the two artifacts that carry every subsequent sales conversation: the buyer-facing reporting surface and the ROI model. Both should be built as if a hostile analyst will audit them, because eventually one will.

The partner motion in quarters two and three runs in parallel across broker relationships and health-system pilots, because their timelines differ so much. Broker relationships need to be seeded well ahead of the benefits planning season; health-system pilots need lead time for governance and integration. Starting both simultaneously means at least one of them lands inside the fiscal year.

The activation gate in quarter three is the most important decision point in the whole plan. If a pilot does not hit its activation target, the correct response is to diagnose onboarding and communications rather than sign more pilots. Signing additional partners while your activation motion is broken multiplies the failure. This is the loop that most teams skip because adding logos feels like progress and fixing activation feels like a step backward.

Quarter four is expansion, and it is where the economics finally work. Adding a service line to an existing employer account or opening a new population with an existing health-system partner carries a fraction of the acquisition cost of a new logo, converts far faster, and produces the reference accounts that shorten the next cycle. The arrow from reference accounts back to broker relationships closes the flywheel: brokers recommend what their other clients have already succeeded with.

One adjacent observation worth carrying into the plan. This sequencing is not unique to telehealth — it is roughly the same shape that worked for vertical SaaS, for value-based care enablement companies, and for any category where a buyer must be convinced that an unfamiliar delivery model produces a familiar financial result. Narrow, instrument, prove, distribute through trusted intermediaries, expand in-account. The industry specifics change; the sequence does not. If you have people on the team who ran GTM in workforce benefits, in specialty pharmacy, or in enterprise vertical software, their instincts transfer more directly than they might assume.

Related questions

Should a telehealth provider ever run direct-to-consumer acquisition in 2027?

Yes, but as a brand and demand-signal layer supporting enterprise sales, not as the primary revenue engine. It works for high-ticket cash-pay services and categories with strong organic search. It rarely works for low-margin acute visits acquired through paid channels.

How long does an enterprise telehealth sales cycle actually take?

Budget two to four quarters for self-insured employer and payer deals, plus a pilot period. Health-system co-management arrangements run longer because of clinical governance, credentialing, and integration work. Modeling these on SaaS-style three-month cycles is a common and expensive planning error.

What is the difference between enrollment and activation, and why does it matter?

Enrollment counts eligible lives; activation counts people who completed a first meaningful interaction. Employers renew on utilization, which activation drives. Reporting enrollment to a client and then facing low utilization at renewal is the most common way telehealth contracts are lost.

Which clinical areas hold up best against retail and health-system competition?

Areas where virtual delivery creates genuine access advantage and requires specialized panels — behavioral health, chronic condition management, and specialties with long in-person wait times. General primary care and acute urgent care have largely commoditized and compete on price and convenience alone.

Do interstate licensure compacts remove the licensing constraint?

They reduce friction substantially but do not eliminate it. Compact participation varies by state and by profession, and clinician recruitment lead time still gates how quickly you can serve a multi-state employer. Treat licensure coverage as a hard input to your sales territory plan.

FAQ

What is the single most important metric for telehealth go-to-market in 2027?

Lifetime value per contracted relationship, not per patient visit, and its ratio to fully loaded acquisition cost. Per-visit thinking hides the fact that acute virtual episodes rarely repeat. Measuring at the account or attributed-population level exposes whether a channel is genuinely profitable or merely busy.

Should we sell to employers or to health plans first?

Employers are usually the faster path: shorter procurement, more accessible decision-makers, and broker networks that provide warm introductions. Health plans have a far larger ceiling but formal procurement, clinical review, and longer timelines. Most providers should win employer references first and use them to open plan conversations.

How do we compete with large retail and pharmacy entrants?

Not on convenience, price, or footprint — those are their strengths. Compete on clinical depth in specific conditions, on specialist panels they do not maintain, and on outcomes documentation for populations they do not manage. Their advantage is breadth; yours has to be depth that produces measurable results.

What role does AI realistically play in the 2027 telehealth playbook?

Mostly operational: triage and intake routing, documentation burden reduction that increases clinician capacity, care-gap identification that drives targeted outreach, and cohort analysis for outcomes reporting. It improves margin and proof quality. It does not solve distribution, and marketing it as a differentiator to clinical buyers rarely lands.

How much should we spend on go-to-market relative to revenue?

There is no reliable universal ratio in this category because delivery cost structures vary enormously between asynchronous and synchronous models. The more useful discipline is channel-level payback: measure fully loaded cost per activated relationship per channel, compare against contribution margin, and reallocate quarterly toward whichever channel pays back fastest.

What is the biggest go-to-market mistake telehealth providers make?

Signing partners before having an outcome claim. A dormant partnership consumes integration engineering, legal review, and account management while routing zero patients, and it teaches the partner's stakeholders that you do not work. Build preliminary proof first, then distribute — the reverse order fails reliably.

Sources

• Centers for Medicare & Medicaid Services — Telehealth — federal coverage and reimbursement guidance
• American Telemedicine Association — industry policy positions and practice guidelines
• Health Affairs — peer-reviewed research on telehealth utilization, access, and cost
• Interstate Medical Licensure Compact — current state participation and physician licensure pathways
• KFF (Kaiser Family Foundation) — employer health benefits survey and payer market analysis
• Business Group on Health — large-employer benefits strategy and virtual care adoption
• Rock Health — digital health funding, market structure, and adoption research
• HealthIT.gov — interoperability, EHR integration, and health data exchange standards
• Agency for Healthcare Research and Quality — evidence reviews on virtual care effectiveness and quality measurement

Related on PULSE

• [Inbound demand-capture GTM playbook in 2027](/knowledge/gp0511)
• [Sales-assisted PLG for mid-market in 2027](/knowledge/gp0510)
• [Reseller and VAR channel GTM playbook in 2027](/knowledge/gp0509)
• [International and geo-expansion GTM playbook in 2027](/knowledge/gp0508)
• [Vertical SaaS go-to-market playbook for healthcare in 2027](/knowledge/gp0507)